Literature DB >> 667856

Photoradiation therapy for the treatment of malignant tumors.

T J Dougherty, J E Kaufman, A Goldfarb, K R Weishaupt, D Boyle, A Mittleman.   

Abstract

Administration of hematoporphyrin derivative i.v. followed by local exposure to red light has resulted in complete or partial response in 111 of 113 cutaneous or s.c. malignant lesions. Tumors treated have included carcinomas of the breast, colon, prostate, squamous cell, basal cell, and endometrium; malignant melanoma; mycosis fungoides; chondrosarcoma; and angiosarcoma. No type has been found to be unresponsive. In several cases complete clearing of chest wall metastatis has been achieved in treated areas. Deep-seated and pigmented tumors required a higher dose of drug for effective treatment than did the more superficial and nonpigmented lesions. A high therapeutic ratio between tumor and skin response has been obtained by allowing at least 3 days between drug injection and exposure to the therapeutic light for 2,5-mg/kg doses and at least a 4-day interval for 5.0-mg/kg doses.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 667856

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  160 in total

1.  Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

Authors:  Eleonora Reginato; Peter Wolf; Michael R Hamblin
Journal:  World J Immunol       Date:  2014-03-27

2.  Lipid composition affects the rate of photosensitized dissipation of cross-membrane diffusion potential on liposomes.

Authors:  Shany Ytzhak; Joseph P Wuskell; Leslie M Loew; Benjamin Ehrenberg
Journal:  J Phys Chem B       Date:  2010-08-12       Impact factor: 2.991

3.  Response of human endometrium and ovarian carcinoma cell-lines to photodynamic therapy.

Authors:  G H Raab; A F Schneider; W Eiermann; H Gottschalk-Deponte; R Baumgartner; W Beyer
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

4.  Nontemplated approach to tuning the spectral properties of cyanine-based fluorescent nanoGUMBOS.

Authors:  Susmita Das; David Bwambok; Bilal El-Zahab; Joshua Monk; Sergio L de Rooy; Santhosh Challa; Min Li; Francisco R Hung; Gary A Baker; Isiah M Warner
Journal:  Langmuir       Date:  2010-08-03       Impact factor: 3.882

Review 5.  A review of progress in clinical photodynamic therapy.

Authors:  Z Huang
Journal:  Technol Cancer Res Treat       Date:  2005-06

6.  High-power light-emitting diode array design and assembly for practical photodynamic therapy research.

Authors:  Eric M Kercher; Kai Zhang; Matt Waguespack; Ryan T Lang; Alejandro Olmos; Bryan Q Spring
Journal:  J Biomed Opt       Date:  2020-04       Impact factor: 3.170

7.  Photoradiation therapy of 9L-gliosarcoma in rats: hematoporphyrin derivative (types I and II) followed by laser energy.

Authors:  M K Cheng; J McKean; B Mielke; J Tulip; D Boisvert
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

8.  Hematoporphyrin derivative and anthracyclines mutually inhibit cellular uptake and toxicity.

Authors:  R M Böhmer; K Hoffmann; G Morstyn
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Use of Cyclodextrins in Anticancer Photodynamic Therapy Treatment.

Authors:  Amina Ben Mihoub; Ludivine Larue; Albert Moussaron; Zahraa Youssef; Ludovic Colombeau; Francis Baros; Céline Frochot; Régis Vanderesse; Samir Acherar
Journal:  Molecules       Date:  2018-08-02       Impact factor: 4.411

10.  Fabrication of ZnPc/protein nanohorns for double photodynamic and hyperthermic cancer phototherapy.

Authors:  Minfang Zhang; Tatsuya Murakami; Kumiko Ajima; Kunihiro Tsuchida; Atula S D Sandanayaka; Osamu Ito; Sumio Iijima; Masako Yudasaka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.